Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
Condition: Malaria Interventions: Biological: R21/Matrix-M - single vial formulation; Biological: R21/Matrix-M - two vial formulation; Biological: Licensed vaccine - Measles-rubella; Biological: Licensed vaccine - Yellow fever; Biological: Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib); Biological: Licensed vaccine - Oral Polio Vaccine (OPV) Sponsors: University of Oxford; Malaria Research and Training Center, Bamako, Mali Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diphtheria | Hepatitis | Hepatitis B | Hepatitis Vaccine | Malaria | Malaria Vaccine | Mali Health | Measles | Measles Vaccine | Polio | Polio Vaccine | Research | Rubella | Rubella Vaccine | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Training | Universities & Medical Training | Vaccines | Whooping Cough (Pertussis) Vaccine